nav1.8

Nav1.8-IN-4 is a potent Nav1.8 channel inhibitor with potential analgesic activity.Nav1.8-IN-4 can be used for pain and neurological related disorders.

Nav1.8-IN-1 (CHEMBL1270208) is an inhibitor of human NaV1.8

PF-06305591 is an effective and selective blocker of voltage-gated sodium channel NaV1.8 (IC50 = 15 nM).

PF 04531083 is a selective blocker of the NaV1.8 channel. PF 04531083 can be used for neuropathic and inflammatory pain studies.

Cyfluthrin binds to voltage-sensitive sodium channel such as Nav 1.8 sodium channel and modify their gating kinetics, thereby disrupting nerve function of pests.

PF-04885614 is a potent inhibitor of NaV1.8, has potential for neurological and neurodevelopmental diseases treatment.

DSP-2230 is a selective blocker of Nav1.7/Nav1.8.

A-803467 is a selective NaV1.8 channel blocker.

ABBV-318 can be used as small molecule Nav1.7/Nav1.8 blockers for the treatment of pain, with IC50 values of 2.8 μM for hNav1.7 and 3.8 μM for hNav1.8. ABBV-318 can be used to study pain-related disorders.

Suzetrigine(VX-548) is an orally active and specific NaV1.8 inhibitor. Suzetrigine has analgesic activity and can be used to study acute pain and neurotransmission.

VX-150 is a highly selective NaV1.8 inhibitor relative to the other sodium channel subtypes (>400-fold).

3'-Methoxydaidzein is a dual isoflavone and Sodium Channel inhibitor. 3'-Methoxydaidzein inhibited NaV1.7, NaV1.8 and NaV1.3 with IC50 of 181 nM, 397 nM and 505 nM, respectively. 3'-Methoxydaidzein was specific for collagen-induced platelet aggregation with IC50 values of 12.3 and 61.5µM, respectively. 3'-Methoxydaidzein acts as an analgesic by inhibiting voltage-gated sodium channels. 3'-Methoxydaidzein showed antioxidant activity and antiplatelet aggregation activity.

Nav1.8 modulator 1 (compound 1) is an effective modulator of Nav1.8, showing potential for pain research.

Nav1.8-IN-11 (Example 1), a Nav1.8 channel inhibitor with an IC50 of 0.1 nM, is utilized in research on pain disorders [1].

Nav1.8-IN-12 (Compound 23 R) serves as an inhibitor of the Nav1.8 channel and is utilized in the research of pain-related diseases [1].

Nav1.8-IN-13 (compound 16), functioning as a Nav1.8 inhibitor with a pIC50 value of 7.9, is referenced as [1].

Nav1.8-IN-5 (Example 1), a voltage-gated sodium channel Nav1.8 inhibitor, is applicable in the research of Nav1.8-mediated diseases including pain, pain-related disorders, and cardiovascular diseases (such as atrial fibrillation) [1].

Nav1.8-IN-7 (Example 116) serves as a selective inhibitor of Nav1.8, demonstrating more than 50% inhibition at 100 nM specifically for Nav1.8. It exhibits an IC50 of 15.6 μM for the hERG channel. This compound holds promise in the field of pain research [1].

Nav1.8-IN-9 (Example 16), a potent Nav1.8 inhibitor with an IC 50 of 0.084 nM, is orally active and holds promise for extensive pain research [1].

Nav1.8-IN-16 (Compound (R)-40) is an orally bioavailable and selective hNaV 1.8 inhibitor with an IC50 of 5.9 nM. It provides analgesic effects by blocking the NaV1.8 channel without significantly affecting other NaV subtypes or the hERG channel. Nav1.8-IN-16 demonstrates dose-dependent pain relief in postoperative and inflammatory pain models and is suitable for pain-related research.

Nav1.8-IN-6 (Compound 2j) is a novel pyridinone amide Nav1.8 channel inhibitor with IC50 values of 513.33 nM in the resting state and 471.81 nM in the partially activated state. Nav1.8-IN-6 also exhibits analgesic activity.

Nav1.8-IN-15 (compound 6) is a potent inhibitor of Nav1.8. It exhibits analgesic properties and holds potential for research in chronic pain management.

Nav1.8-IN-19 (Compound 122) is a potent inhibitor of Nav1.8.

Nav1.8-IN-20 (Compound I) is an orally active inhibitor of the voltage-gated sodium channel Nav1.8, with an IC50 value of 14 nM. It effectively blocks the generation and propagation of action potentials in peripheral nociceptive neurons, providing analgesic effects. Nav1.8-IN-20 shows potential for research in several pain types, including acute, chronic, inflammatory, and neuropathic pain.